Home/Filings/4/0000905148-25-000737
4//SEC Filing

Walker Marlan D 4

Accession 0000905148-25-000737

CIK 0000025743other

Filed

Feb 19, 7:00 PM ET

Accepted

Feb 20, 9:07 PM ET

Size

17.8 KB

Accession

0000905148-25-000737

Insider Transaction Report

Form 4
Period: 2025-02-18
Walker Marlan D
Chief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-02-18+3,46766,032 total
  • Exercise/Conversion

    Common Stock

    2025-02-18+2,31168,343 total
  • Exercise/Conversion

    Common Stock

    2025-02-18+77069,113 total
  • Exercise/Conversion

    Common Stock

    2025-02-18+1,73370,846 total
  • Exercise/Conversion

    Performance Stock Units

    2025-02-183,4670 total
    Exercise: $0.00Common Stock (3,467 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-02-182,3110 total
    Exercise: $0.00Common Stock (2,311 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-02-187700 total
    Exercise: $0.00Common Stock (770 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-02-181,7331,733 total
    Exercise: $0.00Common Stock (1,733 underlying)
Footnotes (4)
  • [F1]Each performance stock unit ("PSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 3,467 shares of common stock of the issuer in settlement of PSUs.
  • [F2]Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 2,311 shares of common stock of the issuer in settlement of RSUs, which vested on July 1, 2024.
  • [F3]Each RSU represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 770 shares of common stock of the issuer in settlement of RSUs, which vested on September 29, 2024.
  • [F4]Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. On February 18, 2025, the reporting person received 1,733 shares of common stock of the issuer in settlement of RSUs, which vested on March 23, 2024.

Documents

1 file

Issuer

TherapeuticsMD, Inc.

CIK 0000025743

Entity typeother

Related Parties

1
  • filerCIK 0001820187

Filing Metadata

Form type
4
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 9:07 PM ET
Size
17.8 KB